These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12868331)

  • 21. [Estrogens in contraception].
    Lauritzen C
    Wien Med Wochenschr; 1987 Oct; 137(18-19):427-32. PubMed ID: 3318154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levonorgestrel versus the "Yuzpe" regimen. New choices in emergency contraception.
    Lee SM; Dunn S; Evans MF
    Can Fam Physician; 1999 Mar; 45():629-31. PubMed ID: 10099801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic trend in acne associated with the menstrual cycle].
    Cersosimo L; Iannucci D; Consalvo F; Orgiu G
    Clin Ter; 1983 Jun; 105(5):411-4. PubMed ID: 6223780
    [No Abstract]   [Full Text] [Related]  

  • 25. [Lybrel and menstrual cessation].
    Nau JY
    Rev Med Suisse; 2007 May; 3(110):1209. PubMed ID: 17564351
    [No Abstract]   [Full Text] [Related]  

  • 26. The effects of hormonal contraceptives on female sexuality: a review.
    Burrows LJ; Basha M; Goldstein AT
    J Sex Med; 2012 Sep; 9(9):2213-23. PubMed ID: 22788250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R; Hirvensalo E; Liukko P; Malmiharju T; Mattila L; Riihiluoma P; Ylöstalo P
    Acta Derm Venereol; 1984; 64(6):517-23. PubMed ID: 6084924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acne: long-term therapy with side effect. Sebaceous gland activity is androgen dependent--acne therapeutic drug is effective as a contraceptive].
    Mehrl J
    Fortschr Med; 1988 Aug; 106(25):50-1. PubMed ID: 2971600
    [No Abstract]   [Full Text] [Related]  

  • 30. [Systemic treatment of acne: recommendations. The French Agency of Sanitary Safety of Health Products].
    Ann Dermatol Venereol; 1999 Mar; 126(3):233-4. PubMed ID: 10394435
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources.
    Joish VN; Boklage S; Lynen R; Schmidt A; Lin J
    J Med Econ; 2011; 14(6):681-9. PubMed ID: 21892859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Systemic treatment of acne: proposal. The French Agency of Sanitary Safety of Health Products].
    Ann Dermatol Venereol; 1999 Mar; 126(3):224-31. PubMed ID: 10394434
    [No Abstract]   [Full Text] [Related]  

  • 36. A cost-benefit analysis of four hormonal contraceptive methods.
    Ortmeier BG; Sauer KA; Langley PC; Bealmear BK
    Clin Ther; 1994; 16(4):707-13. PubMed ID: 7982259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral contraceptives in the treatment of acne.
    Tan JK; Degreef H
    Skin Therapy Lett; 2001 Feb; 6(5):1-3. PubMed ID: 11242137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen-related pancreatis.
    Johnson CA
    Menopause; 2003; 10(5):488; author reply 488. PubMed ID: 14501612
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of premature ovarian failure trial: description of an ongoing clinical trial.
    Cartwright B; Robinson J; Rymer J
    Menopause Int; 2010 Mar; 16(1):18-22. PubMed ID: 20424282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.